Archive · 3 Dec 2025
SPARC Shares Surge 34% on US Court Ruling
SPARC is a company that makes medicines.
Their stock price went up a lot, about 34%, in just two days.
This happened because a court in the US made a decision in their favor.
The court said that the US FDA (a group that checks medicines) should have given SPARC a special voucher called a PRV for one of their medicines, Sezaby.
This voucher can help speed up the checking process for new medicines, which is really valuable.
The medicine Sezaby is used to help babies who have seizures.
The company's bosses own most of the company, about 65.67%.
The CEO of SPARC is happy with the court's decision because it supports what they have always believed.
SPARC shares surged 33.71% in two trading days following a favorable US court ruling.
The US District Court for the District of Columbia granted summary judgment in favor of SPARC regarding the issuance of a Priority Review Voucher (PRV) for Sezaby.
The court ruled that the FDA's withholding of the PRV was contrary to law.
Sezaby is a benzyl alcohol and propylene glycol-free formulation of phenobarbital sodium powder for injection, approved by the US FDA for treating neonatal seizures.
Promoters held a 65.67% stake in SPARC as of September 2025.
- Who
- Sun Pharma Advanced Research Company Ltd (SPARC)
- What
- Shares surged 33.71% in two days due to a favorable US court ruling
- When
- The ruling was granted on an unspecified date, with the stock surge occurring over two trading days
- Where
- The court ruling was from the US District Court for the District of Columbia
- Why
- The court ruled in favor of SPARC regarding the issuance of a Priority Review Voucher (PRV) for its product Sezaby
- Company
- Sun Pharma Advanced Research Company Ltd (SPARC)
- Stock Surge
- 33.71% in two trading days
- Court Ruling
- US District Court for the District of Columbia
- Product
- Sezaby (phenobarbital sodium powder for injection)
- PRV
- Priority Review Voucher
- Promoter Stake
- 65.67% as of September 2025
